NCT06351631 2026-02-20
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
7 trialsNCT05597306 2026-01-08
VenBom
University of Miami
Phase 1 Recruiting
NCT04262141 2026-01-07
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
University of Miami
Phase 2 Active not recruiting
NCT05223920 2025-09-22
MK-3543-005
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT05558696 2025-07-29
MK-3543-004
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT05191797 2024-09-26
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
University of Washington
Phase 1/2 Terminated
NCT02842827 2023-07-11
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 1/2 Completed